Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oral mucosal immunoprophylaxis (OMIP) is a biological intervention composed of a specific mixture of allergen extracts. This mixture includes 0.2 mL of timothy grass extract, 0.2 mL of cat allergen extract, and 0.2 mL of house dust mite extract, totaling a daily dose of 0.6 mL. It is being studied for its potential in the primary prevention of allergic diseases and asthma in high-risk children, aiming to prevent the development of these conditions through early childhood exposure to common allergens.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Oral mucosal immunoprophylaxis.